Skip to main content
logo
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
37.62
+0.64 (1.73%)
Oct 9, 2026, 1:18 PM EDT - Market open

UroGen Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
188.73109.7990.482.7164.3648.04
Revenue Growth
100.27%21.45%9.29%28.52%33.96%307.17%
Gross Profit
171.4697.3481.5273.3556.742.89
Operating Income
-66.65-124.86-95.68-65.54-79.04-92.29
Net Income
-97.64-153.49-126.87-102.24-109.78-110.82
Earnings Per Share
-1.97-3.19-2.96-3.55-4.81-4.96
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
107.98120.46241.71141.4799.9689.81
Total Debt
196.13130.09124.92100.21100.061.49
Net Cash (Debt)
-88.15-9.63116.7941.26-0.188.33
Net Cash Growth
--183.09%---12.73%
Net Cash Per Share
-1.78-0.202.721.43-0.003.95

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-158.92-162.44-96.77-76.38-87.56-84.89
Capital Expenditures
-0.22-0.29-0.3-0.19-0.25-0.75
Free Cash Flow
-159.14-162.73-97.06-76.57-87.81-85.64
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
90.84%88.66%90.18%88.68%88.11%89.27%
Operating Margin
-35.32%-113.73%-105.84%-79.23%-122.82%-192.11%
Pretax Margin
-51.98%-139.74%-137.22%-118.87%-167.86%-227.66%
Profit Margin
-51.73%-139.81%-140.35%-123.61%-170.58%-230.67%
FCF Margin
-84.32%-148.22%-107.37%-92.57%-136.45%-178.27%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
9.589.994.975.603.184.44